MetLife Investment Advisors LLC Takes $659,000 Position in Ignyta Inc (RXDX)

MetLife Investment Advisors LLC bought a new position in shares of Ignyta Inc (NASDAQ:RXDX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 24,664 shares of the biopharmaceutical company’s stock, valued at approximately $659,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in RXDX. Eagle Asset Management Inc. bought a new position in shares of Ignyta during the fourth quarter worth approximately $60,248,000. Gardner Lewis Asset Management L P bought a new position in shares of Ignyta during the fourth quarter worth approximately $49,431,000. Alliancebernstein L.P. increased its stake in shares of Ignyta by 1,414.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,746,002 shares of the biopharmaceutical company’s stock worth $46,618,000 after purchasing an additional 1,630,702 shares during the period. Carillon Tower Advisers Inc. bought a new position in shares of Ignyta during the fourth quarter worth approximately $41,780,000. Finally, Alpine Associates Management Inc. bought a new position in shares of Ignyta during the fourth quarter worth approximately $41,028,000. Institutional investors own 72.28% of the company’s stock.

How to Become a New Pot Stock Millionaire

Ignyta stock opened at $26.98 on Tuesday. Ignyta Inc has a one year low of $5.80 and a one year high of $27.10. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.34.



A number of equities analysts have recently weighed in on RXDX shares. SunTrust Banks lowered Ignyta from a “buy” rating to a “hold” rating and increased their target price for the stock from $25.00 to $27.00 in a research note on Tuesday, December 26th. ValuEngine upgraded Ignyta from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reiterated a “hold” rating and set a $27.00 target price on shares of Ignyta in a research note on Friday, February 9th. Jefferies Group lowered Ignyta from a “buy” rating to a “hold” rating and set a $27.00 target price on the stock. in a research note on Friday, December 22nd. Finally, Ladenburg Thalmann lowered Ignyta from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 26th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Ignyta has a consensus rating of “Hold” and a consensus price target of $27.00.

TRADEMARK VIOLATION NOTICE: “MetLife Investment Advisors LLC Takes $659,000 Position in Ignyta Inc (RXDX)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2018/04/17/metlife-investment-advisors-llc-takes-659000-position-in-ignyta-inc-rxdx.html.

About Ignyta

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply